One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Is “Benign� Urology Benign?
AdrianFernandezMarshall L.Stoller
Human Papillomavirus: One Less Worry for Men Too?
LauraElstMaartenAlbersen
Debunking Four Common Gender Equity Myths
Rena D.MalikaArghavanSallesb
Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma
OscarReig TorrasabcdAkhileshMishraabAlanaChristieaeTiffaniMcKenzieafOreoluwaOnaboluabNirmishSinglaagElizabeth R.PlimackhCristinaSuáreziMoshe C.OrnsteinjR. KatherineAlpaughkRoyEliasabI. AlexBowmanabRenee M.McKayaChristopherPrzybycinlPayalKapurafJamesBrugarolasabBrianRinim
Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer
Daniel J.LeeaRyanHauslerbAnh N.LebGregoryKellybJacquelynPowersbJamesDingbEmilyFeldbHeenaDesaibCaseyMorrisoncAbigailDoucettedPeterGabrieldeRegeneronGenetics Centerf1Renae L.JudygJoellenWeavergRachelKembergScott M.DamrauerhiDaniel J.RadergSusan M.Domchekbd…Kara N.Maxwellbdgi
Continuing the Evolution of Germline Genetics in Prostate Cancer: Tailoring Testing To Enhance Patient Care
Samantha E.GreenbergaMichelle F.Jacobsb
Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy
Maria I.CarloaKyrollisAttallabYousefMazahericSounakGuptadOnurYildirimcSamuel J.MurrayaDevyn T.CoskeyaRiteshKotechaaChung-HanLeeaDarren R.FeldmanaPaulRussobSujataPatileRobert J.MotzeraJonathan A.ColemanbJeremy C.DurackcYing-BeiChenfOguzAkincA.Ari HakimibMartin H.Vossa
Neoadjuvant Treatment in Renal Cell Carcinoma: Transforming Challenges into Opportunities
LauraMarandinoabDanieleRaggiabAndreaNecchiacUmbertoCapitaniobd
A Clinical Decision Aid to Support Personalized Treatment Selection for Patients with Clinical T1 Renal Masses: Results from a Multi-institutional Competing-risks Analysis
Sarah P.PsutkaaRomanGulatibMichael A.S.JewettcKamelFadaakdAntonioFinellicLauraLegerecTodd M.MorganePhillip M.PieroraziofMohamad E.AllaffJephHerringhChristine M.LohseiR.Houston ThompsonjStephen A.BoorjianjThomas D.AtwellkGrant D.SchmitkBrian A.CostellolNilay D.ShahiBradley C.Leibovichj
Predictive Models for Patients with a Renal Mass in the Clinical Trenches Continue to be a Muddy Proposition
RiccardoCampiabcAlexanderKutikovd
Percutaneous Kidney Puncture with Three-dimensional Mixed-reality Hologram Guidance: From Preoperative Planning to Intraoperative Navigation
FrancescoPorpigliaa1EnricoCheccucciabc1DanieleAmparoreaDarioPerettiaFedericoPiramideaSabrinaDe CillisaAlbertoPianaaGabrielNiculescuaPaoloVerriaMatteoManfrediaMassimilianoPoggioaIlariaSturadGiuseppeMigliarettidMarcoCossua1CristianFioria1
Magnetic Resonance Imaging and Targeted Biopsies Compared to Transperineal Mapping Biopsies Before Focal Ablation in Localised and Metastatic Recurrent Prostate Cancer After Radiotherapy
Taimur T.Shahabc1AbiKanthabalanc1MarjorieOtienocMenelaosPavloudRumanaOmardSolaAdelekeefgtuFrancescoGigantichChrisBrew-GraveseNorman R.WilliamscJackGriersoncHaroonMiahcAmrEmaraivAtharHaroonjkArashLatifoltojarelHarbirSidhuehJoeyClementecAlexFreemanmClementOrczykcn…Hashim U.Ahmedab
Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non–muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guérin Immunotherapy
RomanMayra†‡MarkusEcksteinb†‡Ralph M.Wirtzc‡AdemiSantiago-WalkerdMahadiBaigdRameshSundaramdJenna CodyCarcionedRobertStoehrb‡ArndtHartmannb‡ChristianBolenze‡MaximilianBurgera‡WolfgangOttoa‡PhilippErbenf†‡JohannesBreyera†‡
New Evidence and Innovative Approaches to Blinding in Robot-assisted Radical Cystectomy
Caelán MaxHaneyaMaximilian C.KriegmairbMaurice StephanMichelbJens-UweStolzenburgaKarl-FriedrichKowalewskib
Re: Robotic Kidney Transplantation with Regional Hypothermia Versus Open Kidney Transplantation for Patients with End Stage Renal Disease: An Ideal Stage 2B Study
AlbertoBredaAngeloTerritoAndreaGallioli
Re: Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes
RalphPeeker
Re: Radical Prostatectomy for Localized Prostate Cancer: 20-Year Oncological Outcomes from a German High-volume Center
Henkvan der Poel
Re: Abiraterone Acetate and Prednisolone With or Without Enzalutamide for High-risk Non-metastatic Prostate Cancer: A Meta-analysis of Primary Results from Two Randomized Controlled Phase 3 Trials of the STAMPEDE Platform Protocol
ViktorGrünwaldaCarsten-HenningOhlmannbBorisHadaschikc
Re: Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study
MarkusGrabbertaAnca L.GrosubConstantinosZambogloubcChristianGratzkea
Re: Effect of Immunotherapy Time-of-day Infusion on Overall Survival Among Patients with Advanced Melanoma in the USA (MEMOIR): A Propensity Score-matched Analysis of a Single-centre, Longitudinal Study
MatteoSantoniaJavierMolina-CerrillobcFrancescoMassaricRodolfoMontironidEnriqueGrandee
Re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93: Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients
Carlos G.WambierGerard J.Nau
Reply to Carlos G. Wambier and Gerard J. Nau’s Letter to the Editor re: Karin Welén, Ebba Rosendal, Magnus Gisslén, et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. Eur Urol. 2022;81:285–93. Positive Effects of Enzalutamide for Hospitalized COVID-19 Patients: Still No Positive Effect of Enzalutamide for Hospitalized COVID-19 Patients
KarinWelénaEbbaRosendalbEvaFreyhultcWilliam K.OhdMagnusGissléneClasAhlmbAnne-Marie ForsConnollybfAnna K.ÖverbybfAndreasJosefssonagh
Re: Qing Cheng, William Butler, Yinglu Zhou, et al. Pre-existing Castration-resistant Prostate Cancer–like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy. Eur Urol. 2022;81:446–55
IsabelHeideggeraAndreasPircherb
Re: Veerle H. Groen, Karin Haustermans, Floris J. Pos, et al. Patterns of Failure Following External Beam Radiotherapy With or Without an Additional Focal Boost in the Randomized Controlled FLAME Trial for Localized Prostate Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.12.012
Kamal KantSahu
Reply to Kamal Kant Sahu’s Letter to the Editor re: Veerle H. Groen, Karin Haustermans, Floris J. Pos, et al. Patterns of Failure Following External Beam Radiotherapy With or Without an Additional Focal Boost in the Randomized Controlled FLAME Trial for Localized Prostate Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.12.012
Linda G.W.KerkmeijeraFloris J.PosbUulke A.van der HeidebBasIsraëlaCédricDraulanscKarinHaustermansc
Re: Sarah P. Psutka, Roman Gulati, Michael A.S. Jewett, et al. A Clinical Decision Aid to Support Personalized Treatment Selection for Patients with Clinical T1 Renal Masses: Results from a Multi-institutional Competing-risks Analysis. Eur Urol. 2022;81:576–85.
FrancescoMontorsiUmbertoCapitanioGiuseppeRosielloAlessandroLarcher
Re: Christopher Soliman, Niranjan J. Sathianathen, Gianluca Giannarini, et al. There is a Need for a Universal Language in the Reporting and Grading of Complication and Intervention Events to Ensure Comparability and Improvement of Surgical Care. Eur Urol. 2022;81:440–5.
MaraKoelkerMichaelRinkMalte W.Vetterlein
